Skip to main content

Media Relations

Our Press and Media Relations team offers the latest press releases, background information on various topics, and image material for download.

Innovative diagnostic solutions for acute and critical care conditions

We are committed to improving patient outcomes with innovative diagnostic solutions for acute and critical care that allow the diagnosis, outcome prediction, and monitoring of patients with acute medical conditions.

SphingoTec is a privately held company located in Hennigsdorf near Berlin, Germany. With a long history of biomarker discovery, development, and validation, we develop and market innovative IVD solutions for our novel and proprietary blood-based protein biomarkers. 
Our aspiration is to effectively translate scientific advancements into routine clinical practice. We develop biomarkers addressing diagnostically underserved acute and critical care conditions such as sepsis, acute heart failure, and acute kidney injury, which are some of the biggest mortality drivers worldwide.

Subscribe to our Newsletter

Follow the link below to subscribe to our Newsletter & receive updates on our company and products

Subscribe now

Contact our Press & Media Relations Team

Ruxandra Lenz

Head of Marketing & Communications


Latest News

26. March 2024
SphingoTec is pleased to announce the following appointments to its management team: Deborah Bergmann as Managing Director and Chief Executive Officer (CEO), Dr. Florian Uhle as Managing Director and Chief Medical Officer (CMO) and Nicole Witzmann as Chief Financial Officer (CFO).
Read more
05. October 2023
A new, improved formula has been developed for estimating the GFR using kidney function biomarker penKid. According to the data, penKid strongly correlates with the measured GFR (mGFR), while the penKid-based formula for estimating GFR performs better than routinely used equations.
Read more
06. September 2023
A new study and real-world data on the kidney function biomarker penKid underline its potential to monitor kidney function during acute kidney injury (AKI) and RRT and to support liberation decisions from RRT.
Read more

Media Coverage

06. October 2023
SphingoTec GmbH has introduced an improved formula for estimating Glomerular Filtration Rate (GFR) using its kidney function biomarker, penKid. Their data indicates a strong correlation between penKid and measured GFR (mGFR), surpassing the performance of commonly used GFR estimation equations.
Read more
31. August 2023
Point-of-care test developer Boditech Med and biomarker developer SphingoTec announced that they entered a commercialization agreement for a point-of-care blood test to assess kidney function and acute kidney injury.
Read more
10. July 2023
The Thematic Series share thoughts based on scientific data and help the clinician to individualize the different aspects of the patient management. They list the following paper: Evaluation of Proenkephalin A 119–159 for liberation from renal replacement therapy: an external, multicenter pilot study in critically ill patients with acute kidney injury
Read more

Watch our upcoming and latest Webinars on demand

Find out about the latest breakthroughs in clinical diagnostics and get valuable insights from international healthcare experts. To help improve patient management in acute and critical care conditions, we have created a series of webinars that look at the latest diagnostic innovations and how they influence today's clinical practice. Click here to see all available Webinars.


The implementation of a novel kidney function biomarker in clinical routine

Speaker: Univ.-Prof. Dr. med. Gernot Marx | Head of the Department of Intensive Care Medicine and Intermediate Care at the University Hospital RWTH Aachen


Using bio-ADM and penKid for optimization of AHF management in daily clinical practice

Speaker: Prof. John Parissis MD, PhD,  Attikon General Hospital


Using Proenkephalin as a Novel Biomarker to Estimate GFR

Speaker: Prof. Dr. Peter Pickkers, Radboud University, Nijmegen

Press photos for download